Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
about
HIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchThe macrophage: a therapeutic target in HIV-1 infectionCurrent perspectives on HIV-1 antiretroviral drug resistanceThe molecular basis of HIV entryBioinformatic analysis of HIV-1 entry and pathogenesis.Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entrySusceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsSHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant virusesCharacterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsComparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotypingADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitorsClinical use of CCR5 inhibitors in HIV and beyondSelected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropismV3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entryHIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drugNovel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell cultureA common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsUse of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistanceEnhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Coreceptors and HIV-1 pathogenesis.
P2860
Q26746070-7D4EA2A2-A090-40F1-9A1F-A4BFDC70613EQ26823236-BCADE2DA-CA50-4B72-B0BA-AC7D47525987Q26852626-36EBAF5B-5C25-4261-9C19-CED3A8AE3267Q26863686-2CCDB0CD-2B94-4DBC-B8B5-04DD6251A3DCQ27693321-BE478478-0D81-48A8-A8F8-A76865D3BDB8Q28475912-71A13482-D7E6-4530-B2C8-F650AB007D0EQ28477409-BBC21AEC-96C8-4C7B-A98B-A7EBCFE2BD1AQ28742018-1345047D-03AB-4968-89FB-01CF5A04E02FQ30378764-E341729F-23CF-4EF0-A06B-6868E7F4D645Q30654651-F17969ED-8D90-4DF3-AFAB-A182ECDDF103Q33455862-B1BB3C5B-D529-4ABB-8610-E90D11857F40Q33810849-58DE4B3A-8AE5-4E99-A8DB-4A838D4F98D7Q33887352-F6EC61DD-646E-4491-9939-47CF16675616Q33961704-D9E8A2B5-74F6-403F-A875-CE857F940B59Q33966639-0C2781E1-BCFB-4C4C-9FB0-4D872445D4BAQ33990552-5587130B-2743-49A3-81D7-AB0590E9EE86Q34008448-FA079543-8EDF-4D12-9A0C-53F2021E4B93Q34151017-0AC9D145-0B6C-43E8-9D24-353854D27889Q34574397-401CBF66-235C-4CA4-8319-A51BE694B91FQ34641781-6B91002D-0414-4F9B-933B-485E48818589Q35018145-40DAC339-428D-4B59-909C-FC9550162DF0Q35052934-E340E2E5-7018-453D-AAD4-7D29343273F4Q35076868-40371510-8A1A-4B29-BF29-3FACCA864A7BQ35107518-A0FDC846-2FFA-49E9-A1FE-0FF89CB2CD1EQ35274763-204B4CEF-FE0F-42DC-92AC-897687DAA890Q35554970-50F1F2AE-203D-45BA-8D77-13136FCE5AA4Q35665842-13EF90F1-6FDE-4736-9F72-94B64E597070Q36414162-E03FE56D-79A8-4005-940E-643633AD94DAQ36607127-0276C8FE-23C5-4577-B1D7-A9475960454EQ36643050-9B0E5482-087A-4B2F-9C2A-5145B50C0501Q36718337-0C73C770-049A-4354-8134-020110819F6FQ36827946-9BECD7A3-7603-4E7E-A764-4A04B9FE83CAQ36911645-54393720-F219-4B95-B8BF-C06073024535Q36980738-0D418BD3-F4DE-419D-A8D2-69255655C3B1Q37286064-3DAE0369-8CE5-4BF3-92F2-AE9DAE79512AQ37390786-575B3EFF-04BF-4EC4-B274-32D2E7A98CA0Q37421895-B8C716F5-C5D2-4417-97B3-E8CC9F3DBF53Q37452124-4B48B475-9569-4F19-9A3B-8D32D284E59DQ37772888-CBBC1FED-9C7E-4A51-9BF2-CD1492F99DF6Q37824291-E9B70A41-D234-43E8-BA20-B13674E8C1A7
P2860
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@en
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@nl
type
label
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@en
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@nl
prefLabel
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@en
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@nl
P2093
P2860
P356
P1476
Resistance to CCR5 inhibitors ...... fusion peptide of HIV-1 gp41.
@en
P2093
Cleo G Anastassopoulou
John P Moore
Per Johan Klasse
Thomas J Ketas
P2860
P304
P356
10.1073/PNAS.0811713106
P407
P577
2009-03-16T00:00:00Z